1
|
Ruiz R, Galvez-Nino M, Roque K, Montes J, Nuñez M, Raez L, Sánchez-Gambetta S, Jauregui S, Viale S, Smith E, Mas L, Pinto J. P59.30 Genomic Landscape of Lung Cancer in the Young. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
2
|
Galvez-Nino M, Ruiz R, Lozano S, Roque K, Coanqui O, Valdivieso N, Olivera M, Mas L. P07.02 Real World data of Advanced Non-Small Cell Lung Cancer Patients EGFR Mutated from a Peruvian Cohort. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
3
|
Svrcek M, Colle R, Cayre A, Mas L, Bourgoin P, Cohen R, André T, Penault-Llorca F, Radosevic-Robin N. 444P Prevalence of NTRK1/2/3 fusions in dMMR/MSI metastatic colorectal cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
4
|
Paytan T, Ruiz R, Araujo J, Juarez D, Gutierrez J, Morante Z, Aguilar A, Mas L. P09.24 Real-World Data in Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors in a Latin American Institution. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
5
|
Gutierrez J, Araujo J, Ruiz R, Pinto J, Flores C, Morante Z, Amorin E, Mas L. P33.21 Epidemiological Characteristics and Survival in Patients With Lung Cancer in a Peruvian Private Institution Between 2011-2014. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Juarez D, Ruiz R, Gutierrez J, Mas L, Morante Z, Aguilar A, Flores C, Paytan T. P76.32 Real-World Data in Non-Small Cell Lung Cancer with Activating EGFR Mutation Treated with First and Second Generation TKI. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Pino L, Triana I, Mejia J, Camelo M, Galvez-Nino M, Ruiz R, Roque K, Moreno J, Olivera M, Valdiviezo N, Coanqui O, Mas L. P09.14 Predictive Analytics in Real-World Data from Peru: The New Models for Personalized Oncology. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Barrón F, Cardona A, Ruiz-Patiño A, Barron LZ, Corrales-Rodriguez L, Martín C, Sotelo C, Rodríguez J, Ávila J, Mayorga D, Archila P, Mas L, Freitas H, De Lima VC, Otero J, Carranza H, Vargas C, Rosell R. PD1.05 Relevance of Antibiotic Use on Clinical Activity of Immune Checkpoint Inhibitors in Hispanic Patients with Advanced Non-small-cell Lung Cancer (CLICAP-ABs). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.125] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Cardona A, Arrieta O, Ruiz-Patiño A, Barron LZ, Corrales-Rodriguez L, Martín C, Barrón F, Sotelo C, Rodríguez J, Ricaurte L, Ávila J, Mayorga D, Archila P, Otero J, Freitas H, De Lima VC, Mas L, Carranza H, Vargas C, Rosell R. PD2.06 EGFR Inhibitors + Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Cardona A, Arrieta O, Ruiz-Patiño A, Barron LZ, Corrales-Rodriguez L, Martín C, Barrón F, Sotelo C, Rodríguez J, Ricaurte L, Freitas H, De Lima VC, Mas L, Ávila J, Mayorga D, Archila P, Otero J, Carranza H, Vargas C, Rosell R. PD2.03 Exploration of Factors Relating to Immune Response in Patients Treated with Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (NSCLC). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
11
|
Galvez-Nino M, Ruiz R, Roque K, Moreno J, Valdivieso N, Olivera M, Miranda Y, Maquera G, Cabero O, Guillen M, Rojas V, Amorin E, Mas L. P2.05 Real World Data on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Use in Advanced Non-small Cell Lung Cancer from a Latin American Cohort. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.168] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Cardona A, Arrieta O, Ruiz-Patiño A, Barron LZ, Corrales-Rodriguez L, Martín C, Barrón F, Sotelo C, Rodríguez J, Ricaurte L, Ávila J, Mayorga D, Archila P, Freitas H, De Lima VC, Mas L, Otero J, Carranza H, Vargas C, Rosell R. P2.22 Immunotherapy-related Thrombosis: Considerations and Associated Factors in Non-small Cell Lung Cancer (NSCLC) Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Mas L, Patane A, Arrieta O, Soria T, Cardona A, Martín C, Ruiz-Patiño A, Ruiz R, Rioja P, Lozano S, Barron LZ, Barrón F, Corassa M, Freitas H, De Lima VC, Corrales-Rodriguez L, Sotelo C, Rodríguez J, Ricaurte L, Ávila J, Mayorga D, Bravo M, Archila P, Otero J, Carranza H, Vargas C, Rosell R, Remon J. P1.12 Real World Characterization and Treatment Patterns of Patients with Thymic Carcinoma: Lessons from a Latin American Collaborative Study (CLICaP-LATimus). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Cardona A, Ruiz-Patiño A, Arrieta O, Martín C, Raez L, Barron LZ, Barrón F, Ricaurte L, Bravo-Garzón M, Mas L, Corrales-Rodriguez L, Rojas L, Lupinacci L, Perazzo F, Bas C, Carranza O, Pupareli C, Rizzo M, Mendoza RR, Rolfo C, Archila P, Rodríguez J, Sotelo C, Vargas C, Carranza H, Otero J, Pino L, Ortíz C, Laguado P, Rosell R. P2.25 Immunotherapy at Any Line of Treatment Improves Survival in Hispanic Patients with Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) Compared with Chemotherapy (Quijote-CLICaP). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Raez L, Saravia D, Sumarriva D, Ruiz R, Izquierdo P, Cress D, Hunis B, Mas L, Lopes G, Kaen D. P2.16-15 Survival and Clinical Immunotherapy Outcomes in Hispanic Patients vs Non-Hispanic White Patients with Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Auclin E, Marthey L, Mas L, Francois E, Sa Cunha A, Bachet JB, Tougeron D, Vienot A, Lecomte T, Hautefeuille V, Forestier J, Collins M, Abdallah R, Coriat R, Pointet AL, Leroy F, Ksontini F, Williet N, Taieb J. FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma: Update of the AGEO cohort. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Cardona A, Arrieta O, Ruiz-Patiño A, Barrón ZZ, Rojas L, Corrales L, Martin C, Barrón F, Sotelo C, Rodriguez J, Ricaurte L, Ávila J, Mayorga D, Archila P, Otero J, Freitas H, De Lima VC, Mas L, Carranza H, Vargas C, Rosell R. P1.14-61 EGFR Inhibitors Plus Bevacizumab Are Superior Compared to EGFR Inhibitor Monotherapy in Advanced EGFR+ NSCLC Patients with BIM Deletions. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1212] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Mas L, Patané A, Arrieta O, Soria T, Cardona A, Martin C, Ruiz-Patiño A, Rojas L, Ruiz R, Rioja P, Lozano S, Barrón ZZ, Corassa M, Freitas H, De Lima VC, Corrales L, Sotelo C, Rodriguez J, Ricaurte L, Ávila J, Mayorga D, Bravo M, Archila P, Otero J, Carranza H, Vargas C, Rosell R, Remon J. EP1.15-28 Survival of Thymoma Is Extensive in Latin-American Patients: Results from Over 10 Years of Experience (CLICaP-LATimus). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Barrón F, Arrieta O, Cardona A, Ruiz-Patiño A, Barrón ZZ, Rojas L, Corrales L, Martin C, Sotelo C, Rodriguez J, Ávila J, Bravo M, Mayorga D, Archila P, Mas L, Freitas H, De Lima VC, Otero J, Carranza H, Vargas C, Rosell R. EP1.04-45 Relevance of Antibiotic Use on Clinical Activity of Immune Checkpoint Inhibitors in Hispanic Patients with Advanced NSCLC (CLICAP-ABs). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2131] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Cardona A, Ruiz-Patiño A, Arrieta O, Martin C, Raez L, Barrón ZZ, Barrón F, Ricaurte L, Bravo-Garzón M, Mas L, Corrales L, Rojas L, Lupinacci L, Perazzo F, Bas C, Carranza O, Puparelli C, Rizzo M, Ruiz R, Rolfo C, Archila P, Rodriguez J, Sotelo C, Vargas C, Carranza H, Otero J, Pino L, Ortiz C, Laguado P, Rosell R. EP1.04-46 Immunotherapy at Any Line Improves Survival in Hispanic Patients with Advanced Metastatic NSCLC Compared to Chemotherapy (Quijote-CLICaP). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2163] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Flores C, Aguilar A, Enriquez D, Mas L, Schwarz L, Vallejos C. P38 Incidence and Survival of Lung Cancer at Oncosalud - AUNA: A Dynamic Cohort Study. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.07.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
22
|
Saravia D, Raez L, Ruiz R, Munoz-Antonia T, Sumarriva D, Cress D, Hunis B, Chiappori A, Powery H, Izquierdo P, Mas L, Lopes G, Antonia S. PS4 Clinical Outcomes in Hispanic Patients Treated with Checkpoint Inhibitors. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.07.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Cardona A, Arrieta O, Rojas L, Corrales L, Wills B, Oblitas G, Bacon L, Martin C, Cuello M, Mas L, Vargas C, Carranza H, Otero J, Pérez M, González L, Chirinos L, Rosell R. P1.09-013 Profiling Response to Chemotherapy in Malignant Pleural Mesothelioma Among Hispanics (MeSO-CLICaP). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
24
|
Vidal E, Grau-Roma L, Tolosa E, Espinar S, Pérez de Val B, Nofrarías M, Alba A, Allepuz A, López-Soria S, Martínez J, Abarca L, Castellà J, Manteca X, Casanova M, Isidoro-Ayza M, Galindo-Cardiel I, Soto S, Dolz R, Majó N, Ramis T, Segalés J, Mas L, Picart L, Marco A, Domingo M. The Catalan Slaughterhouse Support Network (SESC): An Innovative Diagnostic, Surveillance and Educational Tool. J Comp Pathol 2016. [DOI: 10.1016/j.jcpa.2015.10.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Vidal E, Tolosa E, Espinar S, de Val BP, Nofrarías M, Alba A, Allepuz A, Grau-Roma L, López-Soria S, Martínez J, Abarca ML, Castellà J, Manteca X, Casanova MI, Isidoro-Ayza M, Galindo-Cardiel I, Soto S, Dolz R, Majó N, Ramis A, Segalés J, Mas L, Chacón C, Picart L, Marco A, Domingo M. Six-Year Follow-up of Slaughterhouse Surveillance (2008-2013): The Catalan Slaughterhouse Support Network (SESC). Vet Pathol 2015; 53:532-44. [PMID: 26169387 DOI: 10.1177/0300985815593125] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Meat inspection has the ultimate objective of declaring the meat and offal obtained from carcasses of slaughtered animals fit or unfit for human consumption. This safeguards the health of consumers by ensuring that the food coming from these establishments poses no risk to public health. Concomitantly, it contributes to animal disease surveillance. The Catalan Public Health Protection Agency (Generalitat de Catalunya) identified the need to provide its meat inspectors with a support structure to improve diagnostic capacity: the Slaughterhouse Support Network (SESC). The main goal of the SESC was to offer continuing education to meat inspectors to improve the diagnostic capacity for lesions observed in slaughterhouses. With this aim, a web-based application was designed that allowed meat inspectors to submit their inquiries, images of the lesions, and samples for laboratory analysis. This commentary reviews the cases from the first 6 years of SESC operation (2008-2013). The program not only provides continuing education to inspectors but also contributes to the collection of useful information on animal health and welfare. Therefore, SESC complements animal disease surveillance programs, such as those for tuberculosis, bovine cysticercosis, and porcine trichinellosis, and is a powerful tool for early detection of emerging animal diseases and zoonoses.
Collapse
Affiliation(s)
- E Vidal
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain
| | - E Tolosa
- Agència de Salut Pública de Catalunya, Departament de Salut, Generalitat de Catalunya, Catalonia, Spain
| | - S Espinar
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain
| | - B Pérez de Val
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain
| | - M Nofrarías
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain
| | - A Alba
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain
| | - A Allepuz
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain
| | - L Grau-Roma
- School of Veterinary Medicine and Science, Sutton Bonington Campus, University of Nottingham, Loughborough, UK
| | - S López-Soria
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain
| | - J Martínez
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Catalonia, Spain
| | - M L Abarca
- Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Catalonia, Spain
| | - J Castellà
- Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Catalonia, Spain
| | - X Manteca
- Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Catalonia, Spain
| | - M I Casanova
- Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Catalonia, Spain
| | - M Isidoro-Ayza
- Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Catalonia, Spain
| | - I Galindo-Cardiel
- Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Catalonia, Spain
| | - S Soto
- Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Catalonia, Spain
| | - R Dolz
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain
| | - N Majó
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Catalonia, Spain
| | - A Ramis
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Catalonia, Spain
| | - J Segalés
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Catalonia, Spain
| | - L Mas
- Agència de Salut Pública de Catalunya, Departament de Salut, Generalitat de Catalunya, Catalonia, Spain
| | - C Chacón
- Agència de Salut Pública de Catalunya, Departament de Salut, Generalitat de Catalunya, Catalonia, Spain
| | - L Picart
- Agència de Salut Pública de Catalunya, Departament de Salut, Generalitat de Catalunya, Catalonia, Spain
| | - A Marco
- Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Catalonia, Spain
| | - M Domingo
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalonia, Spain Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Catalonia, Spain
| |
Collapse
|
26
|
Mas L, Hayes Salinas M, Retamozo S, Saurit V, Caeiro F, Diller A, De la Fuente J, Trujillo Salazar P, Alvarellos A, Alvarellos T. AB0018 Tubulointerstitial injury in lupus nephritis and gene expresion of KIM-1. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
Mas L, Saurit V, Cortiñas E, Miretti E, Alvarellos A, Alvarellos T. THU0020 Angiogenesis in Rheumatoid Arthritis: VEGF Expression in Synovial Fluid. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
28
|
Mas L, Saurit V, Cortiñas E, Colazo M, Alvarellos A, Alvarellos T. THU0019 BLyS Expression in Synovial Fluids from Rheumatoid Arthritis Patients. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
29
|
Grange F, Barbe C, Mas L, Granel‐Brocard F, Lipsker D, Aubin F, Velten M, Dalac S, Truchetet F, Michel C, Mitschler A, Arnoult G, Buemi A, Dalle S, Reuter G, Bernard P, Woronoff A, Arnold F. The role of general practitioners in diagnosis of cutaneous melanoma: a population‐based study in France. Br J Dermatol 2012; 167:1351-9. [DOI: 10.1111/j.1365-2133.2012.11178.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- F. Grange
- Service de Dermatologie, Hôpital Robert Debré, Université de Reims‐Champagne‐Ardenne, avenue du général Koenig, 51092 Reims Cedex, France
| | - C. Barbe
- Unité d’Aide Méthodologique, Hôpital Maison Blanche, Reims, France
| | - L. Mas
- Service de Dermatologie, Hôpital Robert Debré, Université de Reims‐Champagne‐Ardenne, avenue du général Koenig, 51092 Reims Cedex, France
| | - F. Granel‐Brocard
- Service de Dermatologie, Hôpital Brabois, Vandoeuvre les Nancy, France
| | - D. Lipsker
- Clinique Dermatologique, Hôpital Civil, Strasbourg, France
| | - F. Aubin
- Service de Dermatologie, Hôpital Saint Jacques, Besançon, France
| | - M. Velten
- Registre des Cancers du Bas‐Rhin and Réseau Français des Registres de Cancers FRANCIM, Strasbourg, France
| | - S. Dalac
- Service de Dermatologie, Hôpital du Bocage, Dijon, France
| | - F. Truchetet
- Service de Dermatologie, Hôpital Beauregard, Thionville, France
| | - C. Michel
- Service de Dermatologie, Hôpital du Moenschberg, Mulhouse, France
| | - A. Mitschler
- Service de Dermatologie, Hôpital Louis Pasteur, Colmar, France
| | - G. Arnoult
- Centre de Recherche et d’Investigation Clinique, Hôpital Maison Blanche, Reims, France
| | - A. Buemi
- Registre des Cancers du Haut‐Rhin and Réseau Français des Registres de Cancers FRANCIM, Mulhouse, France
| | - S. Dalle
- Service de Dermatologie, Hôpital de l’Hôtel‐Dieu, Lyon, France
| | - G. Reuter
- Cabinet de Dermatologie, Strasbourg, France
| | - P. Bernard
- Service de Dermatologie, Hôpital Robert Debré, Université de Reims‐Champagne‐Ardenne, avenue du général Koenig, 51092 Reims Cedex, France
| | - A.S. Woronoff
- CHU de Besançon and Réseau Français des Registres de Cancers FRANCIM; Registre des Tumeurs du Doubs, Besançon, France
| | - F. Arnold
- Association Départementale des Professions de Santé pour le Dépistage des Cancers, Reims, France
| |
Collapse
|
30
|
Vidaurre T, Quintana Truyenque SM, Mantilla R, León M, Doimi F, Vigil CE, Alegría EC, Mas L, Suazo F, Gómez HL. Triple-negative breast cancer tumors in Peruvian patients: Worst prognostic to reach surgery after standard neoadjuvant chemotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e11020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Gallo CS, Innominato P, Casavilca S, Ayon J, Valdivieso N, Huaringa M, Carracedo C, Mas L. 8706 Aggressive management of adult high risk patients with medulloblastoma (MB): 12 years experience at the Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71680-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
Monk B, Mas L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts NW, Pandite LN. A randomized phase II study: Pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5520] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5520 Background: P and L are oral tyrosine kinase inhibitors. P targets VEGFR, PDGFR, and c-Kit. L targets EGFR and HER2 in CC, EGFR overexpression and markers of angiogenesis correlate with poor outcome; the prognostic value of HER2 overexpression remains unclear. Methods: Patients (pts) with measurable stage IVB, persistent or recurrent squamous or adenocarcinoma of the cervix not amenable to curative therapy; 0–1 prior regimens in the metastatic setting; ECOG PS 0–1; were randomized 1:1:1 to each of 3 treatment groups; not prescreened for EGFR or HER2 status. Treatment consisted of P 800mg QD; L 1,500 mg QD; L+P: P 400 mg + L 1,000 mg QD; the doses were escalated to P 800 mg + L 1,500 mg after 20 pts treated at 400 mg + 1,000 mg. Therapy continued until progression (PD), withdrawal due to adverse events (AEs), or withdrawal of consent. Primary endpoint was progression free survival (PFS); secondary overall survival (OS), tumor response (RR), safety. The study had 85% power to detect 80% improvement in PFS. A hierarchical testing procedure was applied comparing L+P vs L followed by L+P vs P and P vs L. The futility boundary was crossed for L + P vs L at the planned interim analysis and this arm was discontinued. Only the comparison of P vs L at the final analysis is reported. Results: Total N = 235 pts: 152 in the monotherapy arms: P (78); L (74). Baseline characteristics were balanced: median age 49 yrs (23–81). Stage IVB: 5%; recurrent 62%; persistent 34%. 86% had prior radiotherapy (45% with chemotherapy); 42% had prior chemotherapy for recurrent/persistent disease. P improved PFS (HR = 0.66; 90% CI 0.48, 0.91 p = 0.013) and OS (HR = 0.67; 90% CI 0.46, 0.99 p = 0.045; median OS for P is 50.7 wks; L is 39.1 wks) with RR for P of 9% and L 5%. Most common AEs (%) P/L were diarrhea (54/58), nausea (36/33), anorexia (28/32), vomiting (20/24); the most common Gr 3 AE was diarrhea (11/13); Gr 4 for any individual AE was ≤ 1%; 1 Gr 5 event of cachexia unrelated to L. Conclusions: PFS and OS were significantly prolonged with P compared to L. P and L both demonstrated a favorable toxicity profile in pts with advanced and recurrent CC. This study demonstrates the potential benefit of P in CC. Further exploration is indicated. [Table: see text]
Collapse
Affiliation(s)
- B. Monk
- UCI Medical Center, Orange, CA; INEN - Medicina, Lima, Peru; Centro Medico San Roque, Tucuman, Argentina; Institut Català d`Oncologia, Hospital Duran I Reyn, Barcelona, Spain; Centre Regional de Lutte contrele Cancer, Marseille, France; Chulalongkorn University, Bangkok, Thailand; GlaxoSmithKline, Collegeville, PA
| | - L. Mas
- UCI Medical Center, Orange, CA; INEN - Medicina, Lima, Peru; Centro Medico San Roque, Tucuman, Argentina; Institut Català d`Oncologia, Hospital Duran I Reyn, Barcelona, Spain; Centre Regional de Lutte contrele Cancer, Marseille, France; Chulalongkorn University, Bangkok, Thailand; GlaxoSmithKline, Collegeville, PA
| | - J. J. Zarba
- UCI Medical Center, Orange, CA; INEN - Medicina, Lima, Peru; Centro Medico San Roque, Tucuman, Argentina; Institut Català d`Oncologia, Hospital Duran I Reyn, Barcelona, Spain; Centre Regional de Lutte contrele Cancer, Marseille, France; Chulalongkorn University, Bangkok, Thailand; GlaxoSmithKline, Collegeville, PA
| | - A. Oaknin
- UCI Medical Center, Orange, CA; INEN - Medicina, Lima, Peru; Centro Medico San Roque, Tucuman, Argentina; Institut Català d`Oncologia, Hospital Duran I Reyn, Barcelona, Spain; Centre Regional de Lutte contrele Cancer, Marseille, France; Chulalongkorn University, Bangkok, Thailand; GlaxoSmithKline, Collegeville, PA
| | - C. Tarpin
- UCI Medical Center, Orange, CA; INEN - Medicina, Lima, Peru; Centro Medico San Roque, Tucuman, Argentina; Institut Català d`Oncologia, Hospital Duran I Reyn, Barcelona, Spain; Centre Regional de Lutte contrele Cancer, Marseille, France; Chulalongkorn University, Bangkok, Thailand; GlaxoSmithKline, Collegeville, PA
| | - W. Termrungruanglert
- UCI Medical Center, Orange, CA; INEN - Medicina, Lima, Peru; Centro Medico San Roque, Tucuman, Argentina; Institut Català d`Oncologia, Hospital Duran I Reyn, Barcelona, Spain; Centre Regional de Lutte contrele Cancer, Marseille, France; Chulalongkorn University, Bangkok, Thailand; GlaxoSmithKline, Collegeville, PA
| | - J. A. Alber
- UCI Medical Center, Orange, CA; INEN - Medicina, Lima, Peru; Centro Medico San Roque, Tucuman, Argentina; Institut Català d`Oncologia, Hospital Duran I Reyn, Barcelona, Spain; Centre Regional de Lutte contrele Cancer, Marseille, France; Chulalongkorn University, Bangkok, Thailand; GlaxoSmithKline, Collegeville, PA
| | - J. Ding
- UCI Medical Center, Orange, CA; INEN - Medicina, Lima, Peru; Centro Medico San Roque, Tucuman, Argentina; Institut Català d`Oncologia, Hospital Duran I Reyn, Barcelona, Spain; Centre Regional de Lutte contrele Cancer, Marseille, France; Chulalongkorn University, Bangkok, Thailand; GlaxoSmithKline, Collegeville, PA
| | - N. W. Stutts
- UCI Medical Center, Orange, CA; INEN - Medicina, Lima, Peru; Centro Medico San Roque, Tucuman, Argentina; Institut Català d`Oncologia, Hospital Duran I Reyn, Barcelona, Spain; Centre Regional de Lutte contrele Cancer, Marseille, France; Chulalongkorn University, Bangkok, Thailand; GlaxoSmithKline, Collegeville, PA
| | - L. N. Pandite
- UCI Medical Center, Orange, CA; INEN - Medicina, Lima, Peru; Centro Medico San Roque, Tucuman, Argentina; Institut Català d`Oncologia, Hospital Duran I Reyn, Barcelona, Spain; Centre Regional de Lutte contrele Cancer, Marseille, France; Chulalongkorn University, Bangkok, Thailand; GlaxoSmithKline, Collegeville, PA
| |
Collapse
|
33
|
Vidaurre T, Olivera M, Gómez H, Pinto J, Doimi F, Velarde R, Abugattas J, Leon J, Mas L, Vigil C. Effect of dose intensity and overexpression of topoisomerase iia on survival in patients with locally advanced breast cancer treated with anthracyclines. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Neciosup S, Quintana S, Gómez H, Mas L, Samanez C, Casanova L, Olivera M, Flores C, León J. 4540 POSTER Cyclophosphamide and cisplatin is an effective treatment in patients with stage II and III seminoma. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71171-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
35
|
Mas L, Montoya CV, Serrepe J, Florian J, Moreno J. Concurrent chemotherapy and radiotherapy for the treatment of cervix uterine cancer at experience in a general hospital. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Mas
- Inst Especializado de Enfermedades Neoplasica, Lima, Peru; Hosp Nacional Almanzor Aguinaga Asenjo, Chiclayo, Peru; Inst Oncologico del Norte, Chiclayo, Peru
| | - C. V. Montoya
- Inst Especializado de Enfermedades Neoplasica, Lima, Peru; Hosp Nacional Almanzor Aguinaga Asenjo, Chiclayo, Peru; Inst Oncologico del Norte, Chiclayo, Peru
| | - J. Serrepe
- Inst Especializado de Enfermedades Neoplasica, Lima, Peru; Hosp Nacional Almanzor Aguinaga Asenjo, Chiclayo, Peru; Inst Oncologico del Norte, Chiclayo, Peru
| | - J. Florian
- Inst Especializado de Enfermedades Neoplasica, Lima, Peru; Hosp Nacional Almanzor Aguinaga Asenjo, Chiclayo, Peru; Inst Oncologico del Norte, Chiclayo, Peru
| | - J. Moreno
- Inst Especializado de Enfermedades Neoplasica, Lima, Peru; Hosp Nacional Almanzor Aguinaga Asenjo, Chiclayo, Peru; Inst Oncologico del Norte, Chiclayo, Peru
| |
Collapse
|
36
|
Vidaurre T, Neciosup S, Pinto J, Torrico C, Gómez H, Mas L, León J, León L, Carracedo C, Vallejos C. Osteosarcoma: Experience at Instituto Especializado de Enfermedades Neoplásicas (1985–2000). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. Vidaurre
- Inst de Enfermedades Neoplasicas, Lima, Peru
| | - S. Neciosup
- Inst de Enfermedades Neoplasicas, Lima, Peru
| | - J. Pinto
- Inst de Enfermedades Neoplasicas, Lima, Peru
| | - C. Torrico
- Inst de Enfermedades Neoplasicas, Lima, Peru
| | - H. Gómez
- Inst de Enfermedades Neoplasicas, Lima, Peru
| | - L. Mas
- Inst de Enfermedades Neoplasicas, Lima, Peru
| | - J. León
- Inst de Enfermedades Neoplasicas, Lima, Peru
| | - L. León
- Inst de Enfermedades Neoplasicas, Lima, Peru
| | | | - C. Vallejos
- Inst de Enfermedades Neoplasicas, Lima, Peru
| |
Collapse
|
37
|
Rodriguez W, Castañeda C, Vallejos C, Casanova L, Carracedo C, León J, Gómez H, Ferreyros G, Flores C, Mas L. Acute lymphatic leukemia: Peruvian experience. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- W. Rodriguez
- Inst de Enfermedades Neoplasicas, Lima, Peru; Instituto de Enfermedades Neoplasicas; Intituto de Enfermedades Neoplasicas, Lima, Peru
| | - C. Castañeda
- Inst de Enfermedades Neoplasicas, Lima, Peru; Instituto de Enfermedades Neoplasicas; Intituto de Enfermedades Neoplasicas, Lima, Peru
| | - C. Vallejos
- Inst de Enfermedades Neoplasicas, Lima, Peru; Instituto de Enfermedades Neoplasicas; Intituto de Enfermedades Neoplasicas, Lima, Peru
| | - L. Casanova
- Inst de Enfermedades Neoplasicas, Lima, Peru; Instituto de Enfermedades Neoplasicas; Intituto de Enfermedades Neoplasicas, Lima, Peru
| | - C. Carracedo
- Inst de Enfermedades Neoplasicas, Lima, Peru; Instituto de Enfermedades Neoplasicas; Intituto de Enfermedades Neoplasicas, Lima, Peru
| | - J. León
- Inst de Enfermedades Neoplasicas, Lima, Peru; Instituto de Enfermedades Neoplasicas; Intituto de Enfermedades Neoplasicas, Lima, Peru
| | - H. Gómez
- Inst de Enfermedades Neoplasicas, Lima, Peru; Instituto de Enfermedades Neoplasicas; Intituto de Enfermedades Neoplasicas, Lima, Peru
| | - G. Ferreyros
- Inst de Enfermedades Neoplasicas, Lima, Peru; Instituto de Enfermedades Neoplasicas; Intituto de Enfermedades Neoplasicas, Lima, Peru
| | - C. Flores
- Inst de Enfermedades Neoplasicas, Lima, Peru; Instituto de Enfermedades Neoplasicas; Intituto de Enfermedades Neoplasicas, Lima, Peru
| | - L. Mas
- Inst de Enfermedades Neoplasicas, Lima, Peru; Instituto de Enfermedades Neoplasicas; Intituto de Enfermedades Neoplasicas, Lima, Peru
| |
Collapse
|
38
|
Gómez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998; 16:2352-8. [PMID: 9667250 DOI: 10.1200/jco.1998.16.7.2352] [Citation(s) in RCA: 124] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy repeated at 3-week intervals is difficult to deliver in elderly patients with non-Hodgkin's lymphoma (NHL). The use of hemopoietic growth factors may decrease the hematologic toxicity of chemotherapy and allow the delivery of full-dose CHOP. PATIENTS AND METHODS We conducted a phase II trial with the addition of granulocyte-macrophage colony-stimulating factor (GM-CSF) to CHOP chemotherapy in NHL patients older than 60 years of age. Twenty-six previously untreated patients were assessable; median age was 67 years (range, 61 to 84 years). CHOP included cyclophosphamide 750 mg/m2 intravenously day 1; doxorubicin 50 mg/m2 intravenously day 1; vincristine 1.4 mg/m2 (2 mg total dose) intravenously day 1; and prednisone 100 mg orally days 1 through 5. GM-CSF 5 microg/kg was administered subcutaneously on days 4 through 13. Cycles were repeated every 21 days for six cycles. Results were analyzed for the total group and for two age subgroups: 61 to 69 years (n = 15) and 70 years or older (n = 11). RESULTS Sixteen patients (62%) achieved a complete response (CR), four patients (15%) achieved a partial response (PR), and six patients (23%) did not respond to therapy. After a median follow-up of 41 months, the median progression-free and overall survival were 19 and 30 months, respectively. Twenty patients completed six cycles. One hundred thirty-eight of the 156 planned cycles were delivered (88%). The relative dose-intensity was 95%. The chemotherapy-induced toxicity was important. Absolute neutrophil count was less than 500/mL in 43% of the cycles, platelet nadir was less than 20,000/mL in 19%, and febrile neutropenia occurred in 21%. There were no grades 3 to 4 mucositis. Treatment-related death occurred in two patients, and was associated with neutropenic septic shock. The toxicity related to GM-CSF was mild hypotension after the cytokine was administered in 7% of cycles. When the results of the study were analyzed by age subgroups, we observed that whereas response and median survival were similar in patients aged 61 to 69 years or 70 years or older, there were significant differences in dose delivery and toxicity. Chemotherapy was delivered in 86 of 90 planned cycles in patients aged 61 to 69 years, but in only 52 of 72 planned cycles in patients aged 70 to 84 years (P = .00008). Absolute neutrophil count was less than 500/mL in 24% of cycles in patients aged 61 to 69 years and 73% of cycles in patients aged 70 years or older (P = .00001). The platelet nadir of less than 20,000/mL occurred in 5% of patients aged 61 to 69 years and in 42% of patients aged 70 years or older (P < .0001). Fever and neutropenia occurred in 8% of patients aged 61 to 69 years and in 42% of patients aged 70 years or older (P < .0001). Mucositis (grades 1 to 2) occurred in 21% of patients aged 61 to 69 years and in 42% of patients aged 70 years or older (P = .006). CONCLUSION CHOP chemotherapy plus GM-CSF is an active regimen in elderly patients with NHL. Despite cytokine support, the toxicity of the regimen is elevated. We have identified two age subgroups (61 to 69 and > or = 70 years) that do not differ in treatment efficacy but show large differences in treatment-related toxicity.
Collapse
Affiliation(s)
- H Gómez
- Department of Medicine, Instituto de Enfermedades de Neoplásicas, Lima, Perú
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Gómez H, Santillana S, Casanova L, Valdivia S, Otero J, Mas L, Vallejos C. 802 Dose intensity (DI) chemotherapy improves disease free survival in elderly aggressive non-Hodgkin's lymphoma (NHL) patients treated with conventional chop. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)96051-e] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
40
|
Mas L, Cayla JS. [The French jurisdictions]. Soins 1988:59-60. [PMID: 3413514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
41
|
Mas L. [Medical follow-up of the French Team]. Union Med Can 1984; 113:634-6. [PMID: 6495438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
42
|
|
43
|
Stescobich D, Donadío R, González Aguilar O, Rozier EG, Mas L. [Anal fistulas of unusual etiology]. Prensa Med Argent 1969; 56:1622-4. [PMID: 5399414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
44
|
Stescobich D, Donadío R, Mas L, Rozier EG, Pundyk C, González Aguilar O. [Anal fistula. Statistics, surgical criteria and results]. Prensa Med Argent 1969; 56:1615-6. [PMID: 5399412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
45
|
Vilanova DL, Rascovan S, Segal Halperin B, Mas L. [Findings in the surgical exploration of congenital arteriovenous fistulas of the extremities]. Prensa Med Argent 1966; 53:2155-60. [PMID: 5996003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|